1Endimiani A, Hujer KM ,Hujer AM, et al. Are we ready for novel detec-tion methods to treat respiratory pathogens in hospital-acquired pneumonia [J] ? Clin Infect Dis,2011 ;52(4) :S373-83.
2ho M, Kaneko T, Goto H, et al. Clinical efficacy of carbapenems on hospi- tal-acquired pneumonia in accordance with the Japanese Respiratory Soci- ety Guidelines for management of HAP[ J). J Infect Chemother,2011 ;17 (3) :147-55.
4El-Gamal MI, Oh CH. Current status of carbapenem antibiotics [ J]. Curr Top Med Chem,2010 ; 10( 18 ) : 1882-97.
5Gomi K, Fujimura S, Fuse K, et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeast- ern region of Japan in 2007 [ J]. J Infect Chemother,2011 ; 17 ( 2 ) :200-6.
6Jia B, Lu P, Huang W, et al. A multicenter, randomized controlled clinical study on biapenem and imipenetn/cilastatin injection in the treatment of respiratory and urinary tract infections [ J ]. Chemotherapy,2010 ;56 (4) : 285 -90.
二级参考文献6
1Quale J,Landman D,Saurina G, et al. Manipulation of a hospital antimicrobial fomnulary to control an outbreak of vancomycin resistant enterococci. Clin Infect Dis, 1996,23 : 1020.
10Arnold HM, McKinnon PS, Augustin KM, et al. Assessment of an alternative meropenemdosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever[J]. Pharmacotherapy, 2009,29(8) : 914.
